35 results about "Myositis" patented technology

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

The invention relates to a Chinese medicament for treating amyotrophy, myositis, myasthenia gravis and muscular dystrophy. The medicament comprises the following raw material medicinal herbs (by weight portion): Ganoderma capense (Lloyd) Teng 5-120, Phellinus igniarius 5-115, Ganoderma apparatus 5-125, the preferred weight ratio of the constituents includes Ganoderma capense (Lloyd) Teng 20, Phellinus igniarius 15, Ganoderma apparatus 25.

The invention discloses a drug for treating child acute benign myositis, aiming to solve the treatment problem of the child acute benign myositis. The drug is prepared from a plurality of Chinese medicinal herbs through processing; and the raw material formula and the weight proportions of the raw materials are as follows: 6-10 parts of aleuritopteris argentea fee, 8-15 parts of loofah sponge, 8-15 parts of six-eared blumea, 6-10 parts of angelica sinensis, 6-10 parts of the root of kudzu vine, 8-15 parts of papaya, 6-10 parts of radix ophiopogonis, 8-15 parts of adenophora tetraphylla and 3-6 parts of fissistigma bracteolatum. Clinical experiments prove that the drug disclosed by the invention is good in curative effect of treating the child acute benign myositis and high in safety, thereby being worth clinical application and popularization.

The invention relates to a preparation for preventing lateolabrax japonicus enteritis and also relates to a preparation method of the preparation for preventing the lateolabrax japonicus enteritis. The preparation for preventing the lateolabrax japonicus enteritis is prepared from the following components in parts by mass: 27 to 35 parts of pomegranate barks, 22 to 26 parts of fresh hydrocotyle sibthorpioides juice, 21 to 26 parts of hibiscus barks, 21 to 25 parts of Rodgersia pinnata Franch., 20 to 25 parts of creeping oxalis, 19 to 23 parts of dandelions, 18 to 24 parts of aconitum gymnandrum maxim, 17 to 23 parts of houttuynia cordata, 17 to 22 parts of cocklebur fruits, 15 to 23 parts of hawthorn fruits, 14 to 20 parts of peruvian groundcherry herb, 14 to 20 parts of common cnidium fruits, 14 to 20 parts of lotus seeds, 13 to 19 parts of roots of Szechwan raspberry, 12 to 18 parts of Myositis sylvatica, 12 to 18 parts of Chinese galls, 10 to 18 parts of lophatherum gracile, 11 to 17 parts of resurrection lily rhizomes, 10 to 16 parts of blackberry lily and the like. The preparation for preventing the lateolabrax japonicus enteritis, provided by the invention, has a good treatment effect on the lateolabrax japonicus enteritis.

A pharmaceutical composition and method reduces statin-related side effects, including myalgia, myositis, myopathy, and myonecrosis. The composition comprises at least one HMG-CoA reductase inhibitor (statin) and vitamin D. The composition may comprise one or more excipient. The pharmaceutical composition is adapted to decrease side effects of said HMG-CoA reductase inhibitors. The excipient may comprise one or more excipient delivery agent providing immediate release, sustained release, extended release and / or combination thereof of said HMG-CoA and / or vitamin D. The amount of the vitamin D may be fixed or variable. A method of treating hyperlipidemia is provided comprising an orally administered pharmaceutical composition having at least one HMG-CoA reductase inhibitor and vitamin D. Preferably, the pharmaceutical composition is administered once per day, via oral, nonoral, transdermal and / or injection drug delivery.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

The present invention is related to new 2-oxo-cyclic compound the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory disease comprising the pain or inflammation caused by rheumatic disease, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and inflammatory syndrome for example, from myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, burns and scar, inflammatory Crohn's disease, Types I diabetes. therefore, it can be used as the therapeutics for treating and preventing inflammatory diseases.

The invention discloses emulsion for decreasing swelling, resisting spasm and relieving pain and a preparation method thereof. The emulsion is used for treating chronic myositis, sprain, arthrodynia and various kinds of neuralgia by applying or external smearing. Taking the preparation of an emulsion finished product of 2000-2100mL as an example, the emulsion respectively comprises the following components: 1300mL of turpentine, 100g of camphor, 100g of peppermint ice, 150g of soft soap and 450mL of distilled water; the invention is local smearing or hot application emulsion and is a skin stimulation medicine. After being locally smeared, the emulsion quickly forms a cool feeling, effectively restrains a spasm state, can achieve the aim of alleviating pain within several minutes, also can be reflected to the deep parts of tissues, can expand capillary vessels, induces metabolism and quickens the absorption of inflammation exudations and the recovery of the tissues. The invention has the functions of enhancing immunological excitement and improving micro-circulation and has the advantages of quick medicine effect, good curative effect, no toxic or side effect and no relapse after curing.

The invention relates to a feed additive for preventing lateolabrax japonicus enteritis and also relates to a preparation method of the feed additive for preventing the lateolabrax japonicus enteritis. The feed additive for preventing the lateolabrax japonicus enteritis is prepared from the following components in parts by mass: 27 to 35 parts of pomegranate barks, 22 to 26 parts of fresh hydrocotyle sibthorpioides juice, 21 to 26 parts of hibiscus barks, 21 to 25 parts of rhizome of paleaceous knotweed, 20 to 25 parts of creeping oxalis, 19 to 23 parts of dandelions, 18 to 24 parts of aconitum gymnandrum maxim, 15 to 23 parts of hawthorn fruits, 14 to 20 parts of peruvian groundcherry herb, 14 to 20 parts of common cnidium fruits, 14 to 20 parts of lotus seeds, 13 to 19 parts of roots of Szechwan raspberry, 12 to 18 parts of myositis, 12 to 18 parts of Chinese galls, 10 to 18 parts of lophatherum gracile, 11 to 17 parts of resurrection lily rhizomes, 10 to 16 parts of blackberry lily and the like. The feed additive for preventing the lateolabrax japonicus enteritis, provided by the invention, can be used for effectively preventing the lateolabrax japonicus enteritis from occurring.

The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

It is an object of the present invention to provide an excellent anti-inflammatory drug for external use that is used for treating inflammation observed in animals (myositis, arthritis, neuritis, tendinitis, tenosynovitis, desmitis, bruise, sprain, etc.), and in particular, for the treatment of bowed tendon observed in horses. The solution of the present invention is an external pharmaceutical composition for preventing or treating inflammation observed in animals, which comprises loxoprofen or a salt thereof as an active ingredient.

Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

The invention provides mebendazole for use in the treatment or prophylaxis of a chronic inflammatory disease, and in particular wherein the chronic inflammatory disease is an autoimmune disease, for example sarcoidosis, systemic lupus erythematosus (SLE), Huntington's disease, end stage renal disease, systemic sclerosis (also called scleroderma), myositis, diabetes type 1, multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, psoriasis, primary biliary cirrhosis, autoimmune hepatitis, Graves' disease, Addison's disease, tuberculosis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, Alzheimer's disease and coeliac disease. A method for the treatment or prophylaxis of a chronic inflammatory disease, comprising administering an effective amount of a mebendazole or a pharmaceutical composition of mebendazole is also provided. The use of mebendazole for the manufacture of a medicament for the treatment of a chronic inflammatory disease is also provided.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

The invention discloses an immunoblotting detection method and application of a myositis-specific autoantibody NXP2 antibody, and constructs a plasmid pCMV-myc-NXP2N containing a Myc tag at the N-terminal (1-500aa) or C-terminal (400-939aa) of NXP2 Or pCMV‑myc‑NXP2C, use the serum of myositis patients to be tested as the primary antibody, and rabbit anti-human IgG H&L as the secondary antibody to determine whether there are NXP2 autoantibodies in the serum of patients with myositis; solve the problem of detecting NXP2 that is not yet commercialized in China The problems of antibody ELISA kits and western blot strips, as well as the high cost and high false positive rate of self-coated NXP2 antigen ELISA kits and the safety of radiolabeled immunoprecipitation.

The invention relates to the technical field of biological medicine and particularly relates to a myositis patient intestinal flora and serum metabolite analysis method. The method comprises steps of conducting 16s rRNA sequencing on an excrement sample of a myositis patient, conducting LC-MS / MS analysis on a serum sample of the myositis patient and conducting ELISA analysis on the serum sample of the myositis patient. ELISA analysis comprises the following steps of detecting the level of inflammatory factors in blood, reading an OD value by using a Bio-Tek microplate reader, calculating the concentration according to a standard curve, and analyzing the change of oxidative stress indexes SOD and MDA of the myositis patient by using an SOD kit and an MDA kit. A problem of incomplete analysis of intestinal colonies and serum of myositis at present is solved.

The invention relates to a seven-link gold label detection card, relates to the technical field of medical science and specifically relates to a novel autoantibody seven-link gold label detection card based on a yeast recombinant expression autoantigen. In order to quickly supply a synthetic judgment basis to a doctor, the invention provides a gold label detection kit. The detection kit comprises an upper shell and a lower shell, wherein a detection unit is arranged in the lower shell; and an observation window is arranged on the upper shell; the detection unit comprises a nitrocellulose membrane, a coated gold label pad, a liquid absorbing pad, a sample pad and a detection belt, wherein the coated gold label pad is arranged at the front end of the upper layer of the nitrocellulose membrane. The seven-link gold label detection card has the beneficial effects that the diagnostic sensibility for systemic lupus erythematosus, dry syndrome, mixed connective tissue diseases and myositis / dermatomyositis can be increased by jointly detecting seven autoantibodies in serum or plasma, the comprehensive analysis for the illness state stage is more benefited, and the gold label detection kit has important significance in judging the type of illness state, tracking and prognosis.

The invention discloses a healthcare feed for increasing the number of soft-shelled turtle laid eggs and improving the quality of soft-shelled turtle laid eggs. The feed is prepared from, by weight, 70-75 parts of bean worms, 8-12 parts of ants, 1-2 parts of oat, 2-4 parts of onions, 1-2 parts of broccoli, 3-5 parts of Chinese chestnuts, 2-3 parts of pawpaw pulp, 1-2 parts of fresh lemon slices, 5-7 parts of Chinese yam, 1-2 parts of medlar, 2-3 parts of radix puerariae, 3-4 parts of black rice, 5-7 parts of black soybeans, 1-2 parts of black corn, 1-3 parts of black fungi, 2-3 parts of Dateplum persimmon, 3-4 parts of mulberries, 13-15 parts of Compositae Eclipta prostrate, 5-7 parts of jambolan, 3-5 parts of pomegranate flowers, 2-4 parts of pittosporum tobira, 10-12 parts of rhizoma cyperi, 4-6 parts of Aristolochia mollissima Hance, 3-5 parts of Atractylodes macrocephala Koidz., 4-5 parts of carnation, 3-4 parts of calendula, 2-3 parts of tartary buckwheat, 2-3 parts of peony flowers, 1-2 parts of myositis and 0.3-0.5 part of medical stone. The feed can increase female soft-shelled turtle laid eggs and improve the quality of female soft-shelled turtle laid eggs.

The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis.

The present invention provides for the treatment of disorders related to TLR7 / 8 overexpression or abherrant activation, wherein the disorder is selected from multiple sclerosis, Alzheimer's Disease, myositis, stroke, ischemia, CNS neuropathies, systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, Guillain-Barr syndrome, alcoholic hepatitis, non-alcoholic steatohepatitis, congenital heart block, autoimmune hepatitis, autoimmune pancreatitis, adult onset Still's disease, drug-induced neurological disorders, and substance addiction, using a compound of Formula (I).

The invention discloses a kit and a method for detecting myositis and myasthenia gravis autoantibodies in human body fluid. The kit comprises a test strip, a working solution and a blocking protein solution, the detection method comprises the following steps: mixing the working solution and the blocking protein solution to form a sample diluent, and adding a to-be-detected sample into the sample diluent; dropwise adding the to-be-detected sample onto the sample pad of the test strip; taking down the water absorption pad and the sample pad on the test strip, washing the carrier membrane, and fixing the water absorption pad and the gold-labeled pad at the two ends of the carrier membrane after the washing is finished; and immersing the gold-labeled pad end of the test strip into the workingsolution, and observing the color development condition. In the detection process, a sample chromatography method is an inverse chromatography method, and a carrier membrane washing method is ultrasonic washing so that the detection sensitivity and specificity are effectively improved, and the antibody can still be detected after strong positive serum is diluted by more than ten thousand times.

Compositions and methods for assessing inflammation in a subject. The present disclosure provides compositions for labeling leukocytes with a 19F-containing perfluoropolyether molecule ex vivo. In some examples, the leukocytes are obtained from the patient, enriched in a whole blood fraction, and then labeled. The labeled cells may be re-introduced into the patient. The leukocytes may accumulate at a site of inflammation, thus permitting non-invasive evaluation of inflammation in patients. The present methods provide a tool for assessing inflammation in a wide variety of autoimmune diseases and may have particular utility in intestinal diseases such as Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cardio myositis.

The present invention relates to novel 2-oxo-cyclic compounds, processes for their preparation and pharmaceutical compositions containing said compounds. The present invention provides a pharmaceutical composition for the prevention and treatment of inflammatory diseases, including pain or inflammation caused by rheumatic diseases, for example, rheumatoid arthritis, juvenile spondyloarthropathy, gout, osteoarthritis, systemic Lupus erythematosus and juvenile arthritis and inflammatory syndromes, eg due to myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, burns and scars, inflammatory Crohn's disease, type I diabetes. Thus, it can be used as a therapeutic method in the treatment and prevention of inflammatory diseases.

The invention discloses a kit and a method for detecting autoantibodies of myositis and myasthenia gravis in human body fluid. The detection kit includes a test strip, a working solution and a closed protein solution; the detection method includes mixing the working solution and the closed protein solution to form sample dilution solution, add the sample to be tested in the sample diluent; add the sample to be tested dropwise on the sample pad of the test strip; remove the absorbent pad and sample pad on the test strip, wash the carrier film, and then wash the carrier film The absorbent pad and the gold standard pad are fixed on both ends of the carrier film; the end of the gold standard pad of the test strip is immersed in the working solution, and the color development is observed. In the detection process of the present invention, the sample chromatographic method is inverted chromatography, and the carrier membrane washing method is ultrasonic washing, which effectively increases the detection sensitivity and specificity, and the strong positive serum can still detect antibodies after being diluted more than 10,000 times.

The present invention is related to new 2-oxo-cyclic compound the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory disease comprising the pain or inflammation caused by rheumatic disease, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and inflammatory syndrome for example, from myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, burns and scar, inflammatory Crohn's disease, Types I diabetes. therefore, it can be used as the therapeutics for treating and preventing inflammatory diseases.